Credit Suisse’s ACELYRIN SLRN Stock Holding History

Credit Suisse’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-19,312	Closed	-$144K	–	3028
2023 Q4	$144K	Sell	19,312 -8,177	-30%	-$69.8K	﹤0.01%	3008
2023 Q3	$280K	Buy	+27,489	New	+$584K	﹤0.01%	2952

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Credit Suisse's SLRN Position: Q1 2024 in Review

Credit Suisse sold out of ACELYRIN (SLRN) in Q1 2024, closing a stake of 19,312 shares — an estimated $144K sold.

Credit Suisse first reported a position in SLRN in Q3 2023 and held it in 2 quarters. The position peaked at $280K in Q3 2023. 109 funds tracked by Wall St. Rank hold SLRN as of Q1 2024.

Credit Suisse reported no remaining ACELYRIN position as of Q1 2024 after selling out during the quarter.
Credit Suisse sold 19,312 ACELYRIN shares in Q1 2024, an estimated $144K.
Credit Suisse first reported a position in ACELYRIN in Q3 2023 and held it in 2 quarters.
Credit Suisse's ACELYRIN position peaked at $280K in Q3 2023.
109 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.